Complement Therapeutic Target-C5
With the first complement inhibitors (Eculizumab, a humanized monoclonal antibody against complement component C5) approved by the US Food and Drug Administration (FDA), the complement system has emerged as an attractive target for upstream intervention in numerous conditions and has advanced into the spotlight of drug discovery.
https://www.creative-biolabs.com/complement-therapeutics/complement-therapeutic-target-c5.htm
